ibudilast Report issue

Small molecule Experimental
AACT ChEMBL DrugBank Drug Central KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Ibudilast is an anti-inflammatory drug used mainly in Japan, which acts as a phosphodiesterase inhibitor, inhibiting the PDE4 subtype to the greatest extent, but also showing significant inhibition of other PDE subtypes.   Wikipedia

Chemistry

  • SMILES: CC(C)C(=O)c1c(nn2ccccc12)C(C)C
  • InChIKey: ZJVFLBOZORBYFE-UHFFFAOYSA-N
  • Mol. Mass: 230.31
  • ALogP: 3.3
  • ChEMBL Molecule:
    ibudilast  
More Chemistry

Pharmacology

Alternative names

3-isobutyryl-2-isopropylpyrazolo(1,5-a)pyridine | av411 | av-411 | ibudilast | ibudilastum | kc 404 | kc-404 | ketas | kp-305 | mn-166

Organizations (22)

Research & Development (22)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (15)

Approved Indications (1)


 

Inflammation

Experimental Indications - Clinical Trial Phases 1-4 (14)


 

Alcoholism (Phase 2)

Amyotrophic Lateral Sclerosis (Phase 2/Phase 3)

Diabetic Neuropathies (Phase 1/Phase 2)

Glioblastoma (Phase 1/Phase 2)

Headache Disorders, Secondary (Phase 1/Phase 2)

Healthy Volunteers (Phase 1)

HIV Infections (Phase 2)

Methamphetamine (Phase 2)

Migraine Disorders (Phase 1)

Multiple Sclerosis, Chronic Progressive (Phase 2)

Opioid-Related Disorders (Phase 2)

Pneumonia, Viral (Phase 2)

Spinal Cord Diseases (Phase 3)

Substance-Related Disorders (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 22
  • # of Trial Organizations: 22

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue